Stock News

$-0.88 EPS Expected for Merus N.V. (MRUS); Aware (AWRE) Sellers Increased By 0.9% Their Shorts

Aware, Inc. (NASDAQ:AWRE) Logo

Aware Inc (NASDAQ:AWRE) had an increase of 0.9% in short interest. AWRE’s SI was 33,600 shares in June as released by FINRA. Its up 0.9% from 33,300 shares previously. With 9,700 avg volume, 4 days are for Aware Inc (NASDAQ:AWRE)’s short sellers to cover AWRE’s short positions. The SI to Aware Inc’s float is 0.28%. It closed at $3.9 lastly. It is down 17.71% since June 13, 2017 and is downtrending. It has underperformed by 30.28% the S&P500. Some Historical AWRE News: ; 24/04/2018 – Aware Recognized as a Top Ten Multifactor Authentication Solution Provider by Enterprise Security Magazine; 22/04/2018 DJ Aware Inc, Inst Holders, 1Q 2018 (AWRE); 24/04/2018 – Aware Inc 1Q Loss/Shr 2c

Analysts expect Merus N.V. (NASDAQ:MRUS) to report $-0.88 EPS on July, 10.They anticipate $0.35 EPS change or 28.46% from last quarter’s $-1.23 EPS. After having $-0.86 EPS previously, Merus N.V.’s analysts see 2.33% EPS growth. The stock increased 1.54% or $0.3 during the last trading session, reaching $19.41. About 11,467 shares traded. Merus N.V. (NASDAQ:MRUS) has declined 2.28% since June 13, 2017 and is downtrending. It has underperformed by 14.85% the S&P500. Some Historical MRUS News: ; 24/05/2018 – Merus Submits Investigational New Drug Application to FDA for MCLA-158; 14/03/2018 – MERUS NV – MERUS GRANTED ONO WORLDWIDE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RESULTING PRODUCTS DEVELOPED THROUGH COLLABORATION; 14/03/2018 – MERUS N.V.: MERUS: ONO PHARMACEUTICALS EXERCISE OF OPTION FOR; 20/03/2018 – Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer; 14/03/2018 – Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibo; 15/05/2018 – Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell; 13/03/2018 – Merus’ Intellectual Property Portfolio Expands with Two New Patents; 14/03/2018 – Merus: To Receive Undisclosed Upfront Payment; 13/03/2018 – Merus’ Intellectual Receives Two New Patents; 14/03/2018 – MERUS NV – ONO HAS AGREED TO FUND RESEARCH ACTIVITIES AT MERUS THAT WILL GENERATE CANDIDATE BICLONICS FOR NEW PROGRAM

Investors sentiment increased to 1.22 in Q1 2018. Its up 0.30, from 0.92 in 2017Q4. It improved, as 2 investors sold Aware, Inc. shares while 7 reduced holdings. 4 funds opened positions while 7 raised stakes. 5.05 million shares or 0.75% less from 5.08 million shares in 2017Q4 were reported. Geode Cap Mngmt Ltd stated it has 0% in Aware, Inc. (NASDAQ:AWRE). Northern Corp accumulated 0% or 53,984 shares. Dimensional Fund Advisors L P accumulated 0% or 1.74M shares. Susquehanna Ltd Liability Partnership holds 0% of its portfolio in Aware, Inc. (NASDAQ:AWRE) for 20,453 shares. Spark Invest Mngmt Limited Liability holds 0% in Aware, Inc. (NASDAQ:AWRE) or 10,900 shares. The New York-based Blackrock has invested 0% in Aware, Inc. (NASDAQ:AWRE). Blair William And Il invested in 0% or 13,000 shares. Gmt Capital invested in 24,600 shares. Vanguard Grp Incorporated holds 0% of its portfolio in Aware, Inc. (NASDAQ:AWRE) for 629,384 shares. 17,750 were accumulated by Fdx Advsrs Incorporated. Tower Research Cap Ltd Liability Co (Trc) invested in 1,039 shares or 0% of the stock. Price T Rowe Associate Md has 12,000 shares. Boston Private Wealth Llc reported 19,000 shares. Ashfield Ptnrs Lc holds 180,108 shares. 862,300 were accumulated by Renaissance Techs Limited Liability Corp.

Aware, Inc. provides software and services for the biometrics industry worldwide. The company has market cap of $84.03 million. The companyÂ’s software products are used in government and commercial biometrics systems to identify or authenticate people. It has a 66.1 P/E ratio. It offers biometrics software products, including biometric services platform, search and match products, software development kits, and application products for fingerprint, facial, and iris modalities that enable various functions in biometrics systems, such as enrollment, analysis, and processing of biometrics images and data on workstations or mobile devices; integration of peripheral biometric capture devices; centralized workflow, transaction processing, and subsystem integration; matching of biometric samples against biometric databases to authenticate or verify identities; and analysis and processing of text identity data.

More important recent Merus N.V. (NASDAQ:MRUS) news were published by: which released: “Merus to Present at the Jefferies 2018 Healthcare Conference” on May 31, 2018, also published article titled: “Analysis: Positioning to Benefit within China Biologic Products, Merus NV, Adient, G1 Therapeutics, Westport Fuel, and …”, published: “Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors” on May 24, 2018. More interesting news about Merus N.V. (NASDAQ:MRUS) was released by: and their article: “Merus NV (MRUS) Says Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer …” with publication date: May 15, 2018.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company has market cap of $439.15 million. The Company’s lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. It currently has negative earnings. The firm also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.

Merus N.V. (NASDAQ:MRUS) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *